Compare Johnson & Johnson (JNJ) vs PayPal Holdings, Inc. (PYPL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson & Johnson vs PayPal Holdings, Inc. — how do they compare? Johnson & Johnson trades at $256.22 (market cap $618.09B), while PayPal Holdings, Inc. trades at $55 (market cap $47.07B). The key difference: Johnson & Johnson is far larger — about 13.1× PayPal Holdings, Inc.'s market cap, and Johnson & Johnson pays the higher dividend (2.09%). Which is the better fit depends on your goals — on Pluang, investors hold Johnson & Johnson for 129 Days and PayPal Holdings, Inc. for 106 Days on average.
| JNJ | PYPL | |
|---|---|---|
Market Cap | $618.09B | $47.07B |
Volume | 6,050,983 | 13,860,099 |
Sector | Health | Financials |
52-Week High | $278.43 | $75.75 |
52-Week Low | $186.00 | $39.08 |
Typical Hold Time | 129 Days | 106 Days |
Enterprise Value | $646.37B | $49.21B |
Dividend Yield | 2.09% | 1.02% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $258.45, up 1.44% with a bearish technical signal despite recent earnings beats. The company maintains strong fundamentals with $94.19B revenue, 21.48% net margin, and robust cash flow. Analyst consensus is bullish with a $286.53 price target, though technical indicators show resistance near $260. Recent news highlights pipeline strength including Icotyde's potential $4.5B peak sales.
JNJ offers stable dividend income and pharmaceutical innovation upside, but faces patent cliff risks and competitive pressures. The stock presents value near current levels with 10.7% upside to consensus target, though technical weakness suggests potential near-term consolidation. Long-term growth drivers include oncology portfolio and Ottava surgical system development.
PayPal (PYPL) trades at $54.95, up 0.62% today, with a bullish technical signal from moving averages and a consensus analyst price target of $56.47. The stock shows strong profitability with a 14.36% net income margin and 24.5% ROE, while recent earnings beats in Q1 and Q2 2026 and a new Meta partnership for AI-powered checkout signal positive momentum. Cash flow remains robust with $1.53B net cash flow in 2025.
PYPL presents a value opportunity with a low P/E of 10.4, but faces risks from competitive pressures in digital payments and slowing branded checkout growth. Wall Street sentiment is mixed with 35.71% buy ratings, yet the stock's current discount to historical highs and cost-cutting initiatives under new CEO Enrique Lores offer potential upside if execution improves.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →About PayPal Holdings, Inc.
PayPal Holdings, Inc. operates as a technology platform company that enables digital and mobile payments on behalf of consumers and merchants. The Company offers online payment solutions. PayPal Holdings serves customers worldwide.
Read more on PYPL →
